Abstract
Product quality is only one aspect of the bigger picture that includes product safety as an equally or more important element when it comes to the sustainability of pharmaceuticals. To ensure the safety and quality of healthcare-related products, in addition to ethical commercialization practices, has been the never-ending task of various regulatory bodies around the world.
The health of nations is more important than the wealth of nations
William James Durant.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abott T, John AV. The cost of US pharmaceutical price reductions: a financial simulation model of R&D decisions. Working paper. Cambridge: National Bureau of Economic Research. 2005. http://www.nber.org/papers/w11114.pdf. Accessed 8 June 2014.
Anello E. A framework for good governance in the public pharmaceutical sector. 2008.
Bond E, Saggi K. Compulsory licensing, price controls, and access to patented foreign products. 2012. http://www.wipo.int/edocs/mdocs/mdocs/en/wipo_ip_econ_ge_4_12/wipo_ip_econ_ge_4_12_ref_saggi.pdf. Accessed 10 May 2014.
Burgess CL, Kand E. “The Next Hot Thing”? DOJ makes cGMP enforcement a top priority. 2013. http://www.pharmacompliancemonitor.com/the-next-hot-thing-doj-makes-cgmp-enforcement-a-top-priority/5625/. Accessed 18 June 2014.
Clarke T. Europeans, U.S. differ over safety of Ranbaxy facility. 2014. http://in.reuters.com/article/2014/06/05/ranbaxy-india-idINKBN0EG1PH20140605. Accessed 5 June 2014.
Competition Policy and Public Procurement: Round table on competition policy and public procurement. Geneva: UNCTAD; 2012. pp. 2–3.
Farrell D et al. Accounting for the cost of US health care: a new look at why Americans spend more. 2008. http://www.mckinsey.com/insights/health_systems_and_services/accounting_for_the_cost_of_us_health_care. Accessed 10 June 2014.
Honig P. International harmonization: an industry perspective. International regulatory harmonization amid globalization of drug development. Washington, DC: National Academy; 2013. http://www.ncbi.nlm.nih.gov/books/NBK174222/#sec_011. Accessed 18 May 2014.
Hooper CL. Pharmaceuticals: economics and regulation. 2008. Library of Economics and Liberty. http://www.econlib.org/library/Enc/PharmaceuticalsEconomicsandRegulation.html#lfHendersonCEE2-125_footnote_nt356. Accessed 10 June 2014.
ICH: 2014. http://www.ich.org/about/faqs.html. Accessed 7 April 2014.
Pharmaceutical Price Controls in OECD Countries Implications for U.S. Consumers, Pricing, Research and Development, and Innovation: Washington, DC: U.S. Department of Commerce—International Trade Administration. 2004. http://www.trade.gov/td/health/DrugPricingStudy.pdf. Accessed 28 June 2014.
Reichman JH, Hasenzahl C. Non-voluntary licensing of patented inventions—historical perspective, legal framework under TRIPS, and an overview of the practice in Canada and the USA. 2003. http://www.ictsd.org/downloads/2008/06/cs_reichman_hasenzahl.pdf. Accessed 5 July 2014.
Reichman JH. Compulsory licensing of patented pharmaceutcal Inventions: evaluating the options. J Law Med Ethics. 2009: 258. http://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=2747&context=faculty_scholarship. Accessed 5 July 2014.
Rosenberg T. The fight against fake drugs. 2014. The New York Times. http://opinionator.blogs.nytimes.com/2014/06/04/the-fight-against-fake-drugs/?_php=true&_type=blogs&hp&rref=opinion&_r=0. Accessed 16 June 2014.
Sridhar D, Gostin L. Caring about health. 2010.
Taiwan FDA:. Related announcements. 2013. http://www.fda.gov.tw/tc/siteList.aspx?pn=1&sid=3014. Accessed 30 June 2014.
Top 10 Drugmakers in Emerging Markets: October 2013. http://www.fiercepharma.com. Accessed 15 Feb 2014.
WHO: Medicines: spurious/falsely-labelled/falsified/counterfeit (SFFC) medicines. 2012. http://www.who.int/mediacentre/factsheets/fs275/en/. Accessed 12 June 2014.
Wileman H, Mishra A. Drug lag and key regulatory barriers in the emerging markets. Perspect Clin Res. 2010:51–56.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Chundru, S. (2015). Sustainable Development for the Healthcare Industry: Vantage Point from Emerging Economies. In: Morgon, P. (eds) Sustainable Development for the Healthcare Industry. Perspectives on Sustainable Growth. Springer, Cham. https://doi.org/10.1007/978-3-319-12526-8_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-12526-8_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-12525-1
Online ISBN: 978-3-319-12526-8
eBook Packages: Business and EconomicsBusiness and Management (R0)